ARID1A loss in clear‑cell tumors
- Ovarian clear-cell carcinoma often shows loss of ARID1A, a tumor-suppressor protein that helps package DNA, and that loss is tightly linked to cancers that arise alongside endometriosis. - The clearest early evidence came in 2012, when investigators found ARID1A loss in 31 of 47 endometriosis-associated ovarian clear-cell or endometrioid carcinomas, including adjacent atypical endometriotic epithelium. - Later studies kept the signal but refined it: ARID1A mutation and protein loss do not always match one-for-one, so pathologists read the stain with morphology and history. (nejm.org)
ARID1A is a DNA-packing gene, and when tumors lose its protein signal, ovarian clear-cell carcinoma moves high on the differential. (nejm.org) (pmc.ncbi.nlm.nih.gov) Clear-cell carcinoma is an epithelial ovarian cancer subtype that has long been linked to endometriosis, the growth of endometrial-type tissue outside the uterus. In a 2010 New England Journal of Medicine study, researchers found ARID1A mutations in 46% of ovarian clear-cell carcinomas and 30% of endometrioid carcinomas they tested. (nejm.org) That paper also showed loss of the ARID1A protein, measured as BAF250a by immunohistochemistry, in 61% of clear-cell carcinomas and 43% of endometrioid carcinomas. The mutation pattern pointed to ARID1A as a recurrent driver in endometriosis-associated ovarian cancer. (nejm.org) A 2012 International Journal of Gynecological Cancer study pushed the timeline earlier. In 31 of 47 endometriosis-associated ovarian clear-cell or endometrioid carcinomas, ARID1A expression was lost, and the same loss appeared in the endometriotic epithelium directly continuous with the tumor. (pmc.ncbi.nlm.nih.gov) That pattern matters because it places ARID1A loss before full malignant transformation, not just after a cancer is already established. In plain terms, the molecular switch seems to flip in precursor tissue sitting next to the eventual tumor. (pmc.ncbi.nlm.nih.gov) The story is not as simple as “mutation equals stain loss.” A 2020 Scientific Reports study found ARID1A loss-of-function mutations in 13% of ovarian endometriosis samples, but those endometriosis samples still retained ARID1A protein expression on immunostaining. (nature.com) In the same 2020 series, most clear-cell carcinomas with ARID1A loss-of-function mutations did lose protein expression, but seven clear-cell carcinomas kept ARID1A staining despite mutation. The authors argued that additional hits, including allelic imbalance or multiple mutations, may be needed before protein loss becomes visible. (nature.com) For cytology and small pelvic samples, that means ARID1A is a clue, not a standalone verdict. A lost stain can support clear-cell carcinoma in the right morphologic and clinical setting, especially with a history of endometriosis, but retained staining does not rule the tumor out. (nejm.org) (nature.com) The practical takeaway from the literature is narrow and useful: read ARID1A alongside the slide, not instead of it. In ovarian clear-cell tumors, the gene’s disappearance is common, early, and informative, but it is still only one part of the case. (pmc.ncbi.nlm.nih.gov) (nature.com)
